We earn a commission from brands on this page, which impacts their display. Advertising disclosure

Compare GLP-1 providers

Explainer

Switching from semaglutide to tirzepatide

By the TreatmentMD editorial team

Updated 6 min read

A smiling woman in a cream cardigan holding up an injection pen

Key takeaways

  • Switching is common. It takes a new prescription, and your clinician picks the timing and your starting dose, since there's no official dose conversion.Obesity PillarsSourceGibble TH, Makin H, et al. Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: results from the PERCEPTIONS survey. Obes Pillars. 2026;19:100288.Open the source All sourcesEli Lilly and CompanySourceLilly Medical. How do you switch patients from a glucagon-like peptide-1 receptor agonist (GLP-1 RA) to Mounjaro® (tirzepatide)? Updated August 25, 2026.Open the source All sources
  • In the one study that compared them directly, people on tirzepatide lost more weight on average, though everyone responds differently.The New England Journal of MedicineRandomized trial · 2025SURMOUNT-5People lost 20.2% of their weight on tirzepatide and 13.7% on semaglutide, in the only trial to compare the two directly.751 people · 72 weeks. Adults with obesity, without diabetes. Open label, funded by Eli Lilly.Tirzepatide as compared with semaglutide for the treatment of obesity. Aronne LJ, et al., 2025.Read the study All sources
  • Expect a short settling-in: you'll usually start low and step up, and your plan will likely want a new approval.U.S. Food and Drug AdministrationSourceFDA prescribing information and Medication Guides for Wegovy® (injection and tablets), Ozempic®, Zepbound® and Mounjaro®: Indications and Usage; Dosage and Administration; Drug Interactions; Adverse Reactions; Clinical Pharmacology; Clinical Studies.All sourcesNovo NordiskSourceNovoCare. Check your coverage for Wegovy®. Checked October 14, 2026.Open the source All sources

By the TreatmentMD editorial team

Thinking about moving from semaglutide to tirzepatide? You're in good company. In one survey of people starting tirzepatide, about one in eight had taken semaglutide before.Obesity PillarsSourceGibble TH, Makin H, et al. Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: results from the PERCEPTIONS survey. Obes Pillars. 2026;19:100288.Open the source All sources

Maybe your progress has slowed, the side effects have been a nuisance, or your coverage changed. Whatever the reason, here's how a switch usually works, what to expect, and why it's a team effort with your clinician.

01The short answer

Can you switch from semaglutide to tirzepatide?

Yes. You'll need a new prescription from your clinician, who decides when to switch and which dose to start on.Eli Lilly and CompanySourceLilly Medical. How do you switch patients from a glucagon-like peptide-1 receptor agonist (GLP-1 RA) to Mounjaro® (tirzepatide)? Updated August 25, 2026.Open the source All sources

Semaglutide is the medicine in Wegovy® and Ozempic®, and tirzepatide is in Zepbound® and Mounjaro®. They work in a similar way: semaglutide acts on the GLP-1 receptor, and tirzepatide on both the GLP-1 and GIP receptors.U.S. Food and Drug AdministrationSourceFDA prescribing information and Medication Guides for Wegovy® (injection and tablets), Ozempic®, Zepbound® and Mounjaro®: Indications and Usage; Dosage and Administration; Drug Interactions; Adverse Reactions; Clinical Pharmacology; Clinical Studies.All sources

You'd take one at a time. The Zepbound® and Wegovy® labels advise against using either with another GLP-1 medicine.U.S. Food and Drug AdministrationSourceFDA prescribing information and Medication Guides for Wegovy® (injection and tablets), Ozempic®, Zepbound® and Mounjaro®: Indications and Usage; Dosage and Administration; Drug Interactions; Adverse Reactions; Clinical Pharmacology; Clinical Studies.All sources

02Why people switch

Why do people switch?

The reasons are usually practical:

  1. Hoping for more

    On average, tirzepatide led to more weight loss in the one study that compared them, so some people try it after a long plateau.The New England Journal of MedicineRandomized trial · 2025SURMOUNT-5People lost 20.2% of their weight on tirzepatide and 13.7% on semaglutide, in the only trial to compare the two directly.751 people · 72 weeks. Adults with obesity, without diabetes. Open label, funded by Eli Lilly.Tirzepatide as compared with semaglutide for the treatment of obesity. Aronne LJ, et al., 2025.Read the study All sources

  2. Side effects

    If semaglutide's side effects have been hard going, a different medicine may suit you better. Everyone's a little different.American Diabetes AssociationSourceAlmandoz JP, Lingvay I, Morales J, Campos C. Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance. Clin Diabetes. 2020;38(4):390-402.Open the source All sources

  3. Cost or coverage

    Plans change which medicines they cover, and cash prices differ, so a switch can follow your coverage.CVS HealthSourceCVS Health. CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options. May 28, 2026.Open the source All sources

03Before you switch

Should you switch, or stay on semaglutide?

It depends on how semaglutide has gone for you. In one review of people who switched, those who'd hit a plateau after losing weight on semaglutide lost about 8% more over six months. Those who hadn't responded much to semaglutide lost about 3%.ObesitySourceBarenbaum SR, Gonzalez A, et al. Real-world weight-loss outcomes in weight-reduced patients treated with tirzepatide. Obesity. 2026;34(Suppl 1).Open the source All sources

So it's worth a chat first. Doctors usually suggest making sure you're on the highest dose that suits you before switching.BMJ Open Diabetes Research & CareSourceAmerican Diabetes Association Professional Practice Committee for Obesity. Pharmacologic treatment of obesity in adults: Standards of Care in Overweight and Obesity. BMJ Open Diabetes Res Care. 2026;13(Suppl 1):e005729.Open the source All sources Happy on semaglutide? There's also a higher Wegovy® dose, 7.2 mg. It's for people who've taken 2.4 mg for at least four weeks and need more weight loss.U.S. Food and Drug AdministrationSourceFDA prescribing information and Medication Guides for Wegovy® (injection and tablets), Ozempic®, Zepbound® and Mounjaro®: Indications and Usage; Dosage and Administration; Drug Interactions; Adverse Reactions; Clinical Pharmacology; Clinical Studies.All sources

Your clinician will weigh your results, side effects, other health conditions, cost and what you prefer.Annals of Internal MedicineSourceQaseem A, Cross JT, et al. Pharmacologic treatments with lifestyle modifications in nonpregnant adults with overweight or obesity in outpatient settings: a living clinical guideline from the American College of Physicians (April 2026). Ann Intern Med. 2026;179.Open the source All sources

04How it works

How does a switch usually go?

Here's the usual path, step by step:

  1. Talk it through

    Your clinician looks at why you'd like to switch and whether it fits, then writes a new prescription.Annals of Internal MedicineSourceQaseem A, Cross JT, et al. Pharmacologic treatments with lifestyle modifications in nonpregnant adults with overweight or obesity in outpatient settings: a living clinical guideline from the American College of Physicians (April 2026). Ann Intern Med. 2026;179.Open the source All sources

  2. Stop one, start the other

    You don't take both. Many clinicians start tirzepatide when your next semaglutide dose would have been due, about a week after your last one.American Diabetes AssociationSourceAlmandoz JP, Lingvay I, Morales J, Campos C. Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance. Clin Diabetes. 2020;38(4):390-402.Open the source All sourcesAmerican Diabetes AssociationSourceWhitley HP, Trujillo JM, Neumiller JJ. Special report: potential strategies for addressing GLP-1 and dual GLP-1/GIP receptor agonist shortages. Clin Diabetes. 2023;41(3):467-473.Open the source All sources

  3. Start at a low dose

    Like any new GLP-1, tirzepatide usually starts low. Zepbound®'s label starts everyone at 2.5 mg for four weeks.U.S. Food and Drug AdministrationSourceFDA prescribing information and Medication Guides for Wegovy® (injection and tablets), Ozempic®, Zepbound® and Mounjaro®: Indications and Usage; Dosage and Administration; Drug Interactions; Adverse Reactions; Clinical Pharmacology; Clinical Studies.All sources

  4. Step up and check in

    Your clinician raises the dose every four weeks or so, based on how you feel and how you're doing.U.S. Food and Drug AdministrationSourceFDA prescribing information and Medication Guides for Wegovy® (injection and tablets), Ozempic®, Zepbound® and Mounjaro®: Indications and Usage; Dosage and Administration; Drug Interactions; Adverse Reactions; Clinical Pharmacology; Clinical Studies.All sources

05Your dose

What dose of tirzepatide do you start on?

Your clinician decides, and there's no official conversion between the two. Lilly, which makes tirzepatide, says it can't give a dose equivalence and leaves the choice to your clinician.Eli Lilly and CompanySourceLilly Medical. How do you switch patients from a glucagon-like peptide-1 receptor agonist (GLP-1 RA) to Mounjaro® (tirzepatide)? Updated August 25, 2026.Open the source All sources

Zepbound®'s label starts everyone at 2.5 mg. Some clinicians start people already on semaglutide a step higher, as one of Lilly's studies in type 2 diabetes did.U.S. Food and Drug AdministrationSourceFDA prescribing information and Medication Guides for Wegovy® (injection and tablets), Ozempic®, Zepbound® and Mounjaro®: Indications and Usage; Dosage and Administration; Drug Interactions; Adverse Reactions; Clinical Pharmacology; Clinical Studies.All sourcesEndocrine PracticeSourceJabbour S, Paik JS, et al. Switching to tirzepatide 5 mg from glucagon-like peptide-1 receptor agonists: clinical expectations in the first 12 weeks of treatment. Endocr Pract. 2024;30(8).Open the source All sources

You may see dose charts online. The best-known ones were made for blood-sugar control during the shortages, not for weight loss, so they're best left to your clinician.American Diabetes AssociationSourceWhitley HP, Trujillo JM, Neumiller JJ. Special report: potential strategies for addressing GLP-1 and dual GLP-1/GIP receptor agonist shortages. Clin Diabetes. 2023;41(3):467-473.Open the source All sources

06Timing

How long do you wait between semaglutide and tirzepatide?

Usually not long. A common plan is to take your first tirzepatide dose on the day your next semaglutide dose was due.American Diabetes AssociationSourceAlmandoz JP, Lingvay I, Morales J, Campos C. Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance. Clin Diabetes. 2020;38(4):390-402.Open the source All sources

Semaglutide does stay in your body for several weeks, which is why you may hear about a "washout".U.S. Food and Drug AdministrationSourceFDA prescribing information and Medication Guides for Wegovy® (injection and tablets), Ozempic®, Zepbound® and Mounjaro®: Indications and Usage; Dosage and Administration; Drug Interactions; Adverse Reactions; Clinical Pharmacology; Clinical Studies.All sources In Lilly's switching studies, though, people moved straight across without one.Eli Lilly and CompanySourceLilly Medical. How do you switch patients from a glucagon-like peptide-1 receptor agonist (GLP-1 RA) to Mounjaro® (tirzepatide)? Updated August 25, 2026.Open the source All sources

If side effects are bothering you, your clinician may suggest waiting until they settle first.American Diabetes AssociationSourceAlmandoz JP, Lingvay I, Morales J, Campos C. Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance. Clin Diabetes. 2020;38(4):390-402.Open the source All sources

07What to expect

What does switching feel like?

A smiling man holding up a blue injection pen

Your stomach may need a few weeks to settle again, which is one reason most people start low. In one study of people with type 2 diabetes moving to tirzepatide, about one in eight noticed stomach side effects. Nearly all were mild.Endocrine PracticeSourceJabbour S, Paik JS, et al. Switching to tirzepatide 5 mg from glucagon-like peptide-1 receptor agonists: clinical expectations in the first 12 weeks of treatment. Endocr Pract. 2024;30(8).Open the source All sources

Appetite control can feel a little lighter for the first few weeks on a starter dose. Weight loss may slow while you step back up, too. That's expected.U.S. Food and Drug AdministrationSourceFDA prescribing information and Medication Guides for Wegovy® (injection and tablets), Ozempic®, Zepbound® and Mounjaro®: Indications and Usage; Dosage and Administration; Drug Interactions; Adverse Reactions; Clinical Pharmacology; Clinical Studies.All sources

Two new habits to know. If you take birth control pills, tirzepatide's label suggests adding a backup or non-pill method for a while: four weeks after you start, and after each step up. And if you take insulin or a sulfonylurea, your clinician may lower those doses when you start.U.S. Food and Drug AdministrationSourceFDA prescribing information and Medication Guides for Wegovy® (injection and tablets), Ozempic®, Zepbound® and Mounjaro®: Indications and Usage; Dosage and Administration; Drug Interactions; Adverse Reactions; Clinical Pharmacology; Clinical Studies.All sources

Our guide to what to expect on tirzepatide walks through the first few months.

08Insurance

Will insurance cover the switch?

Your plan will likely want a new approval, since coverage is for a named medicine. Your clinician sends it, and it can take up to 10 business days.Novo NordiskSourceNovoCare. Check your coverage for Wegovy®. Checked October 14, 2026.Open the source All sources

Some plans prefer one brand over the other, and their lists change. Zepbound®, for example, is back on some CVS Caremark lists from October 2026.CVS HealthSourceCVS Health. CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options. May 28, 2026.Open the source All sources

Already lost weight? That's fine. Some plans, Cigna's among them, count the weight you started at, before any GLP-1, and so does Medicare's GLP-1 Bridge.Cigna HealthcareSourceCigna Healthcare. Coverage policy BEO014: Weight Loss, Glucagon-Like Peptide-1 Agonists, BMI 35 (Zepbound®). Effective September 1, 2026.Open the source All sourcesCenters for Medicare and Medicaid ServicesSourceCMS. Medicare GLP-1 Bridge: information for pharmacies. Checked October 14, 2026.Open the source All sources

On the Bridge, a switch needs a new approval too, and for tirzepatide it covers the Zepbound® KwikPen.Centers for Medicare and Medicaid ServicesSourceCMS. Medicare GLP-1 Bridge: information for pharmacies. Checked October 14, 2026.Open the source All sources Our insurance guide has the details.

09Cost

What does switching cost?

Paying cash, tirzepatide usually costs a little more. Zepbound® is $299 a month at 2.5 mg, $399 at 5 mg and $449 at higher doses when you refill within 45 days.Eli Lilly and CompanySourceLillyDirect. Zepbound® (tirzepatide): self-pay prices and terms. Checked October 14, 2026.Open the source All sources The Wegovy® pen is $349 a month after a new patient's first two fills.Novo NordiskSourceNovoCare. Wegovy® (semaglutide) self-pay prices. Checked October 14, 2026.Open the source All sources

At the programs we rank, compounded tirzepatide costs about $40 to $100 a month more than compounded semaglutide. The good news: it's one price at every dose. We checked those prices in October 2026, and the program confirms yours at checkout.

If you've paid for several months up front, ask how your plan handles a change before you switch.

10Compounded

What if you're on compounded semaglutide?

A smiling woman holding up a small medical vial

The same steps apply. Compounded medicines are made by state-licensed pharmacies for your prescription, and your program's clinician sets your new dose and helps you step up.U.S. Food and Drug AdministrationSourceFDA. Human Drug Compounding. Content current as of June 15, 2026.Open the source All sources

One handy habit: compounded doses are often drawn up in units on a syringe, and units depend on the vial's strength. So your old number of units won't carry over. Know your new dose in milligrams, check the strength on the new vial, and ask to be shown the line on the syringe.U.S. Food and Drug AdministrationSourceFDA. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 26, 2024.Open the source All sources

The big head-to-head study used the brand-name medicines, Zepbound® and Wegovy®. Your clinician will help you choose what fits.The New England Journal of MedicineRandomized trial · 2025SURMOUNT-5People lost 20.2% of their weight on tirzepatide and 13.7% on semaglutide, in the only trial to compare the two directly.751 people · 72 weeks. Adults with obesity, without diabetes. Open label, funded by Eli Lilly.Tirzepatide as compared with semaglutide for the treatment of obesity. Aronne LJ, et al., 2025.Read the study All sources

11Getting started

Ready to explore your options?

Every program we rank offers both semaglutide and tirzepatide, so you can often switch without changing programs. Our ranking puts them side by side, with their prices and what each one includes.

Frequently asked questions.

Is tirzepatide stronger than semaglutide?

In a head-to-head study of adults with obesity, without type 2 diabetes, people on tirzepatide (Zepbound®) lost about 20% of their body weight on average over 72 weeks, against about 14% on semaglutide (Wegovy®).The New England Journal of MedicineRandomized trial · 2025SURMOUNT-5People lost 20.2% of their weight on tirzepatide and 13.7% on semaglutide, in the only trial to compare the two directly.751 people · 72 weeks. Adults with obesity, without diabetes. Open label, funded by Eli Lilly.Tirzepatide as compared with semaglutide for the treatment of obesity. Aronne LJ, et al., 2025.Read the study All sources

Semaglutide is still very effective and widely used, and results vary from person to person.

Will I lose my progress if I switch?

A short pause while you step back up is common, but switching doesn't undo your progress.

In one review, people kept losing weight after they switched.ObesitySourceBarenbaum SR, Gonzalez A, et al. Real-world weight-loss outcomes in weight-reduced patients treated with tirzepatide. Obesity. 2026;34(Suppl 1).Open the source All sources

Can I take semaglutide and tirzepatide together?

No, it's one or the other.

The Zepbound® and Wegovy® labels advise against using either with another GLP-1 medicine.U.S. Food and Drug AdministrationSourceFDA prescribing information and Medication Guides for Wegovy® (injection and tablets), Ozempic®, Zepbound® and Mounjaro®: Indications and Usage; Dosage and Administration; Drug Interactions; Adverse Reactions; Clinical Pharmacology; Clinical Studies.All sources

What do I do with leftover semaglutide?

Ask your pharmacist or clinician what to do with it, and don't use it alongside your new medicine.

Can I switch back to semaglutide?

Yes, with your clinician.

People sometimes go back for side effects, cost or coverage, usually starting low and stepping up again.U.S. Food and Drug AdministrationSourceFDA prescribing information and Medication Guides for Wegovy® (injection and tablets), Ozempic®, Zepbound® and Mounjaro®: Indications and Usage; Dosage and Administration; Drug Interactions; Adverse Reactions; Clinical Pharmacology; Clinical Studies.All sources

Can I switch from the Wegovy® pill to tirzepatide?

Yes, with your clinician.

Tirzepatide only comes as a weekly shot, and the same steps apply: a new prescription, a low starting dose and gentle steps up.U.S. Food and Drug AdministrationSourceFDA prescribing information and Medication Guides for Wegovy® (injection and tablets), Ozempic®, Zepbound® and Mounjaro®: Indications and Usage; Dosage and Administration; Drug Interactions; Adverse Reactions; Clinical Pharmacology; Clinical Studies.All sources

The bottom line

Switching from semaglutide to tirzepatide is common and usually simple: a new prescription, a low starting dose and a few weeks to settle in.

Your clinician sets the timing and the dose, and your plan may want a new approval.

When you're ready, compare programs on our ranking.

By the TreatmentMD editorial team

Medical disclaimerThis content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting any weight-loss program or medication. Individual results may vary.

Sources18 sources, and product and safety information
  1. 1Gibble TH, Makin H, et al. Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: results from the PERCEPTIONS survey. Obes Pillars. 2026;19:100288. doi.org
  2. 2Lilly Medical. How do you switch patients from a glucagon-like peptide-1 receptor agonist (GLP-1 RA) to Mounjaro® (tirzepatide)? Updated August 25, 2026. medical.lilly.com
  3. 3Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36. doi.org
  4. 4FDA prescribing information and Medication Guides for Wegovy® (injection and tablets), Ozempic®, Zepbound® and Mounjaro®: Indications and Usage; Dosage and Administration; Drug Interactions; Adverse Reactions; Clinical Pharmacology; Clinical Studies.
  5. 5NovoCare. Check your coverage for Wegovy®. Checked October 14, 2026. novocare.com
  6. 6Almandoz JP, Lingvay I, Morales J, Campos C. Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance. Clin Diabetes. 2020;38(4):390-402. doi.org
  7. 7CVS Health. CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options. May 28, 2026. cvshealth.com
  8. 8Barenbaum SR, Gonzalez A, et al. Real-world weight-loss outcomes in weight-reduced patients treated with tirzepatide. Obesity. 2026;34(Suppl 1). doi.org
  9. 9American Diabetes Association Professional Practice Committee for Obesity. Pharmacologic treatment of obesity in adults: Standards of Care in Overweight and Obesity. BMJ Open Diabetes Res Care. 2026;13(Suppl 1):e005729. doi.org
  10. 10Qaseem A, Cross JT, et al. Pharmacologic treatments with lifestyle modifications in nonpregnant adults with overweight or obesity in outpatient settings: a living clinical guideline from the American College of Physicians (April 2026). Ann Intern Med. 2026;179. doi.org
  11. 11Whitley HP, Trujillo JM, Neumiller JJ. Special report: potential strategies for addressing GLP-1 and dual GLP-1/GIP receptor agonist shortages. Clin Diabetes. 2023;41(3):467-473. doi.org
  12. 12Jabbour S, Paik JS, et al. Switching to tirzepatide 5 mg from glucagon-like peptide-1 receptor agonists: clinical expectations in the first 12 weeks of treatment. Endocr Pract. 2024;30(8). doi.org
  13. 13Cigna Healthcare. Coverage policy BEO014: Weight Loss, Glucagon-Like Peptide-1 Agonists, BMI 35 (Zepbound®). Effective September 1, 2026. cigna.com
  14. 14CMS. Medicare GLP-1 Bridge: information for pharmacies. Checked October 14, 2026. cms.gov
  15. 15LillyDirect. Zepbound® (tirzepatide): self-pay prices and terms. Checked October 14, 2026. lilly.com
  16. 16NovoCare. Wegovy® (semaglutide) self-pay prices. Checked October 14, 2026. novocare.com
  17. 17FDA. Human Drug Compounding. Content current as of June 15, 2026. fda.gov
  18. 18FDA. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 26, 2024. fda.gov

Product information

  • Zepbound® (tirzepatide) is a prescription-only injectable medication FDA-approved for chronic weight management in adults with obesity, or adults with overweight who have at least one weight-related medical condition. It is also approved for the treatment of moderate to severe obstructive sleep apnea in adults with obesity, and should be used in combination with a reduced-calorie diet and increased physical activity.
  • Ozempic® (semaglutide) is a prescription-only injectable medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. It is not FDA-approved for weight loss; however, weight reduction has been observed in some individuals with type 2 diabetes using the medication.
  • Mounjaro® (tirzepatide) is a prescription-only injectable medication FDA-approved for the treatment of type 2 diabetes. It is not FDA-approved for weight loss; however, weight reduction has been observed in some individuals using the medication.
  • Wegovy® (semaglutide) is a prescription-only injectable or oral medication FDA-approved for chronic weight management in adults with obesity, or adults with overweight and at least one weight-related medical condition, when used alongside a reduced-calorie diet and increased physical activity.
  • All medications require a medical evaluation and prescription from a licensed healthcare provider. Individual results may vary.

Important safety information

  • Compounded semaglutide and tirzepatide are prepared by state-licensed pharmacies and are not FDA approved. The FDA does not review their safety, effectiveness or quality, and clinical trial results for brand-name drugs do not carry over to them.
  • Semaglutide and tirzepatide carry a boxed warning for a risk of thyroid C-cell tumors, based on animal studies, and are not for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2, or who is pregnant. Other warnings include pancreatitis, gallbladder problems, and a higher risk of low blood sugar when combined with insulin or a sulfonylurea. The most common side effects are digestive, such as nausea, vomiting, diarrhea and constipation.
  • This is a high-level summary, not a complete list. A licensed clinician will review your health history to decide whether a GLP-1 medication is right for you.

Our #1 pick

Ready to start? welludr. is our pick.

The lowest advertised price on our list, with unlimited clinician messaging.

Visit welludr.Compare providers